Chris’s patent caseload has included an array of technologies in the pharmaceutical, immunology, medical device, agritech, and computing systems fields. In the area of pharmaceuticals, Chris has experience representing plaintiffs and defendants in patent infringement actions related to antibiotics, cancer-treatment drugs, sleep aid medications, and fungal infection ointments in district courts around the country. Chris has participated on several trial teams in high-stakes, high-profile litigation in pharmaceutical and agritech cases, and has collaborated on matters before the US Court of Appeals for the Federal Circuit and the US Supreme Court. Notably, Chris was one of the first attorneys to litigate novel issues of statutory construction of the Biologics Price Competition and Innovation Act.
Apart from his patent work, Chris has extensive litigation experience, including a very active critical motions and appellate practice. Chris has personally argued in three courts of appeal and has drafted critical motions and briefs in numerous subject areas, including employment, environmental, defamation, copyright, tax, and complex commercial litigation law.
Chris served as law clerk to the Hon. Todd M. Hughes for the US Court of Appeals for the Federal Circuit, and the Hon. Gail J. Standish for the US District Court for the Central District of California.
During law school, Chris served a Notes Editor on the George Washington Law Review, a member of the Moot Court Board, and a representative of the law school in the George Washington University Student Association.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.